ACN vs CTSH: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ACN is the larger of the two ($133.77B market cap): the incumbent the market prices for continued execution (14.23x forward earnings, beta 1.00). CTSH is the smaller challenger ($26.43B), cheaper on forward earnings (9.42x): more room to run, but more to prove. If you believe ACN earns its premium (14.23x forward earnings, so the market expects more from it), ACN fits. If you believe in paying less for profit, CTSH fits at 9.42x.

ACN vs CTSH: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricACNCTSHWhat it tells you
Market cap$133.77B$26.43BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E14.239.42Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E16.7010.79Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.000.83Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range63% of range44% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book4.271.80How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: CTSH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ACN and CTSH affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ACN and CTSH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ACN and CTSH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Accenture (ACN) do?

Accenture is a global professional services company that helps businesses, governments, and other organizations across more than 120 countries build digital infrastructure, optimize operations, and accelerate growth. The company operates across five major service areas: Strategy and Consulting, Technology Services, Operations, Industry X (engineering and manufacturing digitization), and Song (marketing and customer experience). It earns revenue through a mix of consulting engagements, managed services contracts, and increasingly fixed-price, outcome-based arrangements, with managed services growing faster at roughly 10% year over year as of Q2 FY2026. The company serves clients in virtually every major industry vertical, from financial services and health to communications and government, and generates the majority of its revenue outside North America.

Full ACN guide

What does Cognizant Technology Solutions (CTSH) do?

Cognizant Technology Solutions is one of the largest global IT services and consulting firms, with roughly 359,900 employees and a delivery model centered on India-based talent serving mostly North American and European clients. It builds, runs, and modernizes software and business processes across four segments, Health Sciences, Financial Services, Products and Resources, and Communications, Media and Technology, and is increasingly positioning around generative AI, cloud migration, and data services (including a roughly $600 million acquisition of AI-infrastructure provider Astreya).

Full CTSH guide

ACN vs CTSH: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • ACN drivers: Enterprise AI implementation at scale; Shift to recurring, outcome-based revenue.
  • CTSH drivers: AI-led services and deal momentum; Margin expansion via Project Leap.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The most structural bear-case concern is AI cannibalization: if generative AI and agentic AI tools automate the coding, testing, documentation, and process management that make up a significant portion of Accenture's billable work, clients may require fewer hours per engagement, compressing revenue without a commensurate reduction in costs. For CTSH, the core risk is that AI automation erodes the labor-arbitrage economics of traditional IT services, pressuring pricing and headcount-linked revenue over time.

ACN or CTSH: which should you pick?

If the story you believe is ACN's (Enterprise AI implementation at scale), ACN is the more direct way to own it; if it is CTSH's (AI-led services and deal momentum), CTSH is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ACN and CTSH guides.

ACN vs CTSH: the full fundamentals

ACN. At ~$226.54 on November 20, 2026, Accenture trades at about 16.7x trailing earnings and ~14.2x forward estimates, up from roughly 10 to 13x in June after the autumn rally, though still below its 5-year average near 25x. Consensus calls for fiscal 2027 EPS of ~$14.66 on ~$77.5 billion of revenue, and trailing free cash flow of ~$10.7 billion covers the dividend (about a 48% payout ratio) and buybacks. The next report, for the quarter ending November 30, is scheduled for December 17, 2026, with consensus near ~$3.95 EPS on ~$19.4 billion of revenue.

CTSH. CTSH's valuation is low for a profitable large-cap, and it fell further after the third-quarter report: at $59.21 on November 20, 2026 the shares trade near 11x trailing earnings and 6.3x EV to EBITDA, about 27% below where they began the year, because the market is skeptical about IT-services growth in an AI world. The 25 covering analysts carry an average target near $69.42, though November brought cuts from Deutsche Bank (to $66) and BofA (to $70). Fourth-quarter consensus is about $1.51 of EPS on roughly $5.55 billion of revenue, with results expected in early 2027; figures change with each quarterly report and share-price move.

Headline figures (approximate, November 2026): ACN shows revenue (fy2026, ended aug 31 2026) ~$74.2 billion (+~6.5% YoY), q4 fy2026 revenue ~$18.7 billion (+~6.2% YoY), q4 fy2026 eps ~$3.29 (vs ~$3.18 consensus), net income (fy2026) ~$8.4 billion (~11.3% net margin); CTSH shows revenue (ttm) ~$21.9B, Q3 2026 growth ~+4.6% YoY, q3 2026 results revenue ~$5.66B; adjusted EPS ~$1.49 vs ~$1.46 consensus, net income (ttm) ~$2.6B, ~11.8% net margin, operating margin (ttm) ~16.3%.

The bottom line: ACN vs CTSH

ACN and CTSH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined ACN and CTSH exposure against your real portfolio. It is not an investment adviser.

Wondering how ACN or CTSH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Accenture

Ask Walnut's AI anything about ACN and see how it fits what you own.

FAQ

What is the difference between ACN and CTSH?

+

Accenture is a global professional services company that helps businesses, governments, and other organizations across more than 120 countries build digital infrastructure, optimize operations, and accelerate growth. Cognizant Technology Solutions is one of the largest global IT services and consulting firms, with roughly 359,900 employees and a delivery model centered on India-based talent serving mostly North American and European clients. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ACN or CTSH the better stock?

+

Neither is universally better. ACN is the larger incumbent; CTSH is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ACN or CTSH?

+

On forward P/E (as of November 2026), ACN trades at 14.23x and CTSH at 9.42x, so CTSH is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ACN and CTSH?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ACN vs CTSH?

+

ACN: The most structural bear-case concern is AI cannibalization: if generative AI and agentic AI tools automate the coding, testing, documentation, and process management that make up a significant portion of Accenture's billable work, clients may require fewer hours per engagement, compressing revenue without a commensurate reduction in costs. Accenture is also exposed to a slowdown or outright contraction in U.S. federal government spending, as DOGE-driven budget cuts have already created headwinds in its government and public services segment. Additionally, the broader macroeconomic environment and client caution around large discretionary IT spending create near-term bookings softness, which prompted multiple analyst price target reductions earlier in 2026. After the autumn rally the stock trades a little below the ~$236 mean analyst target across 25 firms, and it fell ~9% in the month to November 20, 2026, so sentiment on the AI question remains fragile. A larger acquisition program (~$8 billion planned for fiscal 2027) adds integration and regulatory-timing risk. Finally, foreign currency fluctuations across more than 120 countries add meaningful volatility to reported results, since the majority of revenue is earned outside the United States. CTSH: The core risk is that AI automation erodes the labor-arbitrage economics of traditional IT services, pressuring pricing and headcount-linked revenue over time. Near-term demand is soft: clients are cutting discretionary spending, delaying projects, and focusing on cost, and revenue growth has stayed around 4.5% to 4.6% year over year in the second and third quarters of 2026, with Deutsche Bank projecting organic growth near 2% by year end. Cognizant also faces intense competition and pricing pressure from larger peer Accenture and India-based rivals such as TCS, Infosys, Wipro, and HCL. Client concentration in banking, financial services, and health sciences means a downturn in those verticals hits results, and a large share of delivery in India exposes the company to wage inflation, currency swings, immigration/visa policy, and geopolitical risk. Execution on Project Leap and integrating acquisitions add further uncertainty. Immigration policy became a live issue again in October 2026, with headlines on a US suspension affecting the employer-sponsored green-card (PERM) process, a pressure point for any firm that relies on India-based talent working onsite in the US. Sentiment turned again after the October 29 report: the shares fell about 16% over the month to November 20, 2026 as Deutsche Bank downgraded to Hold ($66 target) and BofA cut its target to $70 from $91, and a narrowed 2026 outlook leaves little room for a weak fourth quarter.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ACN or CTSH; figures are approximate and dated (as of November 2026). Verify current data before investing.